\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\ \(73\)\
\-\ serial\\ radiographs\\ as\\ a\\ means\\ to\\ track\\ the\\ progression\\/regression\\ of\\ the\\ ossification\\.\\ \\ cold\\ compresses\\,\\ ice\\,\\ elevation\\,\\ and\\ immobilization\\ to\\ treat\\ symptoms\\.\ \(0\)\
\-\ initial\\ a\\-p\\ radiograph\\ of\\ the\\ left\\ hip\\ shows\\ pinning\\ of\\ the\\ left\\ femoral\\ fracture\\ and\\ indistinct\\ flocculent\\ calcifications\\ in\\ the\\ lateral\\ quadriceps\\ musculature\\.\\ a\\-p\\ radiograph\\ of\\ the\\ left\\ hip\\ three\\ weeks\\ later\\ shows\\ that\\ the\\ ossifications\\ in\\ the\\ lateral\\ quadriceps\\ musculature\\ is\\ better\\ defined\\.\ \(0\)\
\-\ myositis\\ ossificans\ \(28\)\
\-\ myositis\\ ossificans\ \(28\)\
\-\ extraskeletal\\ chondrosarcoma\\ or\\ osteosarcoma\ \(0\)\
\-\ pseudomalignant\\ osseous\\ tumor\\ of\\ soft\\ tissue\ \(0\)\
\-\ soft\\ tissue\\ sarcoma\\ such\\ as\\ mfh\\ \\(before\\ maturation\\ of\\ myositis\\ ossificans\\)\ \(0\)\
\-\ this\\ 37\\-year\\-old\\ woman\\ with\\ diagnosed\\ autosomal\\ dominant\\ polycystic\\ kidney\\ disease\\ for\\ 10\\ years\\,\\ has\\ progressed\\ to\\ end\\ stage\\ renal\\ disease\\ and\\ required\\ a\\ renal\\ transplant\\.\\ \\ while\\ recovering\\ from\\ surgery\\ and\\ on\\ immunosuppression\\,\\ she\\ sustained\\ a\\ left\\ hip\\ fracture\\.\\ the\\ fracture\\ was\\ reduced\\ and\\ pinned\\ and\\ a\\ fibular\\ graft\\ was\\ placed\\.\\ radiographs\\ after\\ surgery\\ and\\ 3\\ weeks\\ postoperatively\\ when\\ the\\ patient\\ had\\ complaints\\ of\\ left\\ \\"hip\\"\\ swelling\\ and\\ pain\\,\\ along\\ with\\ mild\\ erythema\\.\ \(0\)\
\-\ sixty\\-75\\ \\%\\ of\\ patients\\ with\\ myositis\\ ossificans\\ have\\ a\\ history\\ of\\ trauma\\ or\\ surgery\\.\\ the\\ sites\\ most\\ commonly\\ involved\\ after\\ trauma\\ are\\ the\\ elbow\\,\\ thigh\\ and\\ less\\ frequently\\ the\\ shoulder\\ and\\ calf\\ and\\ the\\ more\\ common\\ the\\ the\\ proximal\\ than\\ distal\\ extremities\\.\\ after\\ prosthetic\\ placement\\,\\ the\\ soft\\ tissues\\ of\\ the\\ hips\\ and\\ knees\\ are\\ most\\ commonly\\ involved\\.\\ participants\\ of\\ high\\-impact\\ sports\\ \\(wrestling\\,\\ football\\,\\ and\\ rugby\\)\\ are\\ at\\ the\\ greatest\\ risk\\ for\\ developing\\ myositis\\ ossificans\\ due\\ to\\ blunt\\ trauma\\ sustained\\ during\\ participation\\.\\ \\ the\\ initial\\ clinical\\ signs\\ following\\ \\ trauma\\ are\\ non\\-specific\\ and\\ may\\ include\\ localized\\ warmth\\,\\ erythema\\,\\ tenderness\\,\\ and\\ occasionally\\ decreased\\ range\\ of\\ motion\\.\\ \\ in\\ a\\ period\\ of\\ 1\\-4\\ weeks\\ after\\ surgery\\ or\\ trauma\\,\\ the\\ soft\\ tissue\\ swelling\\ becomes\\ a\\ more\\ discrete\\ mass\\.\\ \\ \\ \\ \\ \ \(0\)\
\-\ in\\ the\\ acute\\ stage\\ prior\\ to\\ development\\ of\\ a\\ defined\\ mass\\,\\ \\ an\\ inflammatory\\ or\\ infective\\ process\\ such\\ as\\ thrombophlebitis\\ or\\ cellulitis\\ may\\ be\\ considered\\ clinically\\.\\ \\ \\ \\ \\ \\ \ \(0\)\
\-\ in\\ 7\\-10\\ days\\ after\\ the\\ traumatic\\ episode\\,\\ periosteal\\ reaction\\ may\\ be\\ seen\\.\\ initially\\ a\\ soft\\ tissue\\ mass\\ mass\\ have\\ more\\ flocculent\\ amorphous\\ calcifications\\ and\\ may\\ resemble\\ a\\ soft\\ tissue\\ malignancy\\.\\ within\\ 6\\ to\\ 8\\ weeks\\,\\ the\\ mass\\ develops\\ a\\ zonal\\ pattern\\ with\\ mature\\ ossification\\ peripherally\\ characteristic\\ of\\ myositis\\ ossificans\\.\\ \\ radiography\\ and\\ ct\\ show\\ this\\ zonal\\ pattern\\.\\ \\ \ \(0\)\
\-\ in\\ the\\ acute\\ stages\\,\\ treatment\\ includes\\ cold\\ compresses\\ along\\ with\\ rest\\,\\ elevation\\,\\ and\\ immobilization\\ followed\\ by\\ graduated\\ range\\ of\\ motion\\ exercises\\.\\ \\ if\\ pain\\ and\\ decreased\\ range\\ of\\ motion\\ persist\\ beyond\\ 6\\ months\\ to\\ a\\ year\\,\\ patients\\ can\\ be\\ treated\\ surgically\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ossificans\\:\\ 0\\.32874080353499824\ \(0\)\
\-\ myositis\\:\\ 0\\.3124891400142017\ \(0\)\
\-\ the\\:\\ 0\\.23339077070282296\ \(0\)\
\-\ and\\:\\ 0\\.18368985735464943\ \(0\)\
\-\ of\\:\\ 0\\.1556509662947021\ \(0\)\
\-\ soft\\:\\ 0\\.14944928274175343\ \(0\)\
\-\ hip\\:\\ 0\\.1437611616687835\ \(0\)\
\-\ flocculent\\:\\ 0\\.13827380614454887\ \(0\)\
\-\ zonal\\:\\ 0\\.13827380614454887\ \(0\)\
\-\ trauma\\:\\ 0\\.13585948523756322\ \(0\)\
\-\ tissue\\:\\ 0\\.12271609510563472\ \(0\)\
\-\ after\\:\\ 0\\.11348484049752092\ \(0\)\
\-\ weeks\\:\\ 0\\.11216061520476175\ \(0\)\
\-\ compresses\\:\\ 0\\.10958026784499941\ \(0\)\
\-\ range\\:\\ 0\\.10891952301747079\ \(0\)\
\-\ motion\\:\\ 0\\.10880742390892865\ \(0\)\
\-\ quadriceps\\:\\ 0\\.10635346997719357\ \(0\)\
\-\ musculature\\:\\ 0\\.10178150887946373\ \(0\)\
\-\ surgery\\:\\ 0\\.10061791531123221\ \(0\)\
\-\ cold\\:\\ 0\\.09970229825622332\ \(0\)\
\-\ sustained\\:\\ 0\\.09557978466620597\ \(0\)\
\-\ may\\:\\ 0\\.09417805868369374\ \(0\)\
\-\ immobilization\\:\\ 0\\.09132281288202689\ \(0\)\
\-\ mass\\:\\ 0\\.08935624563278914\ \(0\)\
\-\ ossification\\:\\ 0\\.08701903990249392\ \(0\)\
\-\ elevation\\:\\ 0\\.08530876232348086\ \(0\)\
\-\ erythema\\:\\ 0\\.08467164116105665\ \(0\)\
\-\ to\\:\\ 0\\.08187598413077611\ \(0\)\
\-\ or\\:\\ 0\\.08138120218324947\ \(0\)\
\-\ left\\:\\ 0\\.07979972386699241\ \(0\)\
\-\ fracture\\:\\ 0\\.07977138925701652\ \(0\)\
\-\ more\\:\\ 0\\.07707261562740725\ \(0\)\
\-\ involved\\:\\ 0\\.07502970165656674\ \(0\)\
\-\ pseudomalignant\\:\\ 0\\.0748220296511325\ \(0\)\
\-\ stage\\:\\ 0\\.07451704093828011\ \(0\)\
\-\ participants\\:\\ 0\\.07149644379064739\ \(0\)\
\-\ graduated\\:\\ 0\\.07149644379064739\ \(0\)\
\-\ are\\:\\ 0\\.07101361460838103\ \(0\)\
\-\ pattern\\:\\ 0\\.0698611727121084\ \(0\)\
\-\ in\\:\\ 0\\.06983399203410465\ \(0\)\
\-\ commonly\\:\\ 0\\.06923974204473493\ \(0\)\
\-\ calcifications\\:\\ 0\\.06829196610493092\ \(0\)\
\-\ extraskeletal\\:\\ 0\\.06730670110354917\ \(0\)\
\-\ rugby\\:\\ 0\\.06730670110354917\ \(0\)\
\-\ infective\\:\\ 0\\.06730670110354917\ \(0\)\
\-\ defined\\:\\ 0\\.06675469948811945\ \(0\)\
\-\ ossifications\\:\\ 0\\.06581131721178933\ \(0\)\
\-\ mfh\\:\\ 0\\.06581131721178933\ \(0\)\
\-\ pinned\\:\\ 0\\.06581131721178933\ \(0\)\
\-\ participation\\:\\ 0\\.06454698814631289\ \(0\)\
\-\ maturation\\:\\ 0\\.06345177649341639\ \(0\)\
\-\ immunosuppression\\:\\ 0\\.06345177649341639\ \(0\)\
\-\ wrestling\\:\\ 0\\.06345177649341639\ \(0\)\
\-\ swelling\\:\\ 0\\.06297940053381533\ \(0\)\
\-\ initial\\:\\ 0\\.06277254019045836\ \(0\)\
\-\ along\\:\\ 0\\.06269052098036328\ \(0\)\
\-\ resemble\\:\\ 0\\.061621574524691115\ \(0\)\
\-\ radiograph\\:\\ 0\\.060945852582168884\ \(0\)\
\-\ prosthetic\\:\\ 0\\.06083984958713372\ \(0\)\
\-\ radiographs\\:\\ 0\\.06069039323715654\ \(0\)\
\-\ such\\:\\ 0\\.06019110836944841\ \(0\)\
\-\ postoperatively\\:\\ 0\\.06012619063293127\ \(0\)\
\-\ renal\\:\\ 0\\.05827073090817387\ \(0\)\
\-\ decreased\\:\\ 0\\.05796121591733179\ \(0\)\
\-\ recovering\\:\\ 0\\.05776664991455834\ \(0\)\
\-\ be\\:\\ 0\\.056938413442145556\ \(0\)\
\-\ as\\:\\ 0\\.056387566422935485\ \(0\)\
\-\ amorphous\\:\\ 0\\.05635715061825002\ \(0\)\
\-\ pinning\\:\\ 0\\.05515472300827566\ \(0\)\
\-\ shows\\:\\ 0\\.05491942536221185\ \(0\)\
\-\ thrombophlebitis\\:\\ 0\\.054790133922499706\ \(0\)\
\-\ 10\\:\\ 0\\.054716906643705716\ \(0\)\
\-\ fibular\\:\\ 0\\.054106245977107774\ \(0\)\
\-\ indistinct\\:\\ 0\\.05378456145606657\ \(0\)\
\-\ warmth\\:\\ 0\\.053176734988596784\ \(0\)\
\-\ persist\\:\\ 0\\.053176734988596784\ \(0\)\
\-\ patients\\:\\ 0\\.05264009231114874\ \(0\)\
\-\ means\\:\\ 0\\.05234192310892963\ \(0\)\
\-\ track\\:\\ 0\\.052081523335700285\ \(0\)\
\-\ ice\\:\\ 0\\.05158428601224554\ \(0\)\
\-\ exercises\\:\\ 0\\.05158428601224554\ \(0\)\
\-\ calf\\:\\ 0\\.050890754439731865\ \(0\)\
\-\ sports\\:\\ 0\\.050890754439731865\ \(0\)\
\-\ acute\\:\\ 0\\.0506195715818002\ \(0\)\
\-\ develops\\:\\ 0\\.05045897559558145\ \(0\)\
\-\ mature\\:\\ 0\\.05004879493092204\ \(0\)\
\-\ stages\\:\\ 0\\.05004879493092204\ \(0\)\
\-\ blunt\\:\\ 0\\.049658154249112976\ \(0\)\
\-\ peripherally\\:\\ 0\\.049658154249112976\ \(0\)\
\-\ polycystic\\:\\ 0\\.04946959642941761\ \(0\)\
\-\ hips\\:\\ 0\\.04928527622486282\ \(0\)\
\-\ football\\:\\ 0\\.04910500734364165\ \(0\)\
\-\ cellulitis\\:\\ 0\\.04910500734364165\ \(0\)\
\-\ graft\\:\\ 0\\.048755937475215165\ \(0\)\
\-\ knees\\:\\ 0\\.048755937475215165\ \(0\)\
\-\ beyond\\:\\ 0\\.048755937475215165\ \(0\)\
\-\ most\\:\\ 0\\.04869837287744897\ \(0\)\
\-\ progressed\\:\\ 0\\.048586820062635226\ \(0\)\
\-\ discrete\\:\\ 0\\.04842111939824972\ \(0\)\
\-\ autosomal\\:\\ 0\\.04825870015176042\ \(0\)\
\-\ radiography\\:\\ 0\\.04778989233310298\ \(0\)\
\-\ treat\\:\\ 0\\.04734643817890685\ \(0\)\
\-\ transplant\\:\\ 0\\.04679016375998594\ \(0\)\
\-\ greatest\\:\\ 0\\.04679016375998594\ \(0\)\
\-\ have\\:\\ 0\\.046744990256022204\ \(0\)\
\-\ lateral\\:\\ 0\\.04643836809789096\ \(0\)\
\-\ thigh\\:\\ 0\\.04602067134359553\ \(0\)\
\-\ with\\:\\ 0\\.04580704932646284\ \(0\)\
\-\ sites\\:\\ 0\\.04566140644101344\ \(0\)\
\-\ reduced\\:\\ 0\\.04487968150345605\ \(0\)\
\-\ occasionally\\:\\ 0\\.04487968150345605\ \(0\)\
\-\ developing\\:\\ 0\\.0447738490167234\ \(0\)\
\-\ becomes\\:\\ 0\\.0447738490167234\ \(0\)\
\-\ osteosarcoma\\:\\ 0\\.04426425011757202\ \(0\)\
\-\ better\\:\\ 0\\.04416602254925361\ \(0\)\
\-\ elbow\\:\\ 0\\.04416602254925361\ \(0\)\
\-\ dominant\\:\\ 0\\.04378446985055955\ \(0\)\
\-\ surgically\\:\\ 0\\.04341988076478359\ \(0\)\
\-\ serial\\:\\ 0\\.043070810896357115\ \(0\)\
\-\ chondrosarcoma\\:\\ 0\\.04290169348377717\ \(0\)\
\-\ episode\\:\\ 0\\.042818424708447364\ \(0\)\
\-\ localized\\:\\ 0\\.042029171634590794\ \(0\)\
\-\ end\\:\\ 0\\.04117254294427688\ \(0\)\
\-\ periosteal\\:\\ 0\\.04117254294427688\ \(0\)\
\-\ period\\:\\ 0\\.04090579085066638\ \(0\)\
\-\ rest\\:\\ 0\\.04045888399007443\ \(0\)\
\-\ reaction\\:\\ 0\\.039802381392067786\ \(0\)\
\-\ disease\\:\\ 0\\.03927874230254594\ \(0\)\
\-\ sarcoma\\:\\ 0\\.03924798771241724\ \(0\)\
\-\ clinically\\:\\ 0\\.03888106820925889\ \(0\)\
\-\ development\\:\\ 0\\.03867854177320593\ \(0\)\
\-\ complaints\\:\\ 0\\.03852986270641802\ \(0\)\
\-\ frequently\\:\\ 0\\.03852986270641802\ \(0\)\
\-\ before\\:\\ 0\\.0378243933723889\ \(0\)\
\-\ characteristic\\:\\ 0\\.0378243933723889\ \(0\)\
\-\ osseous\\:\\ 0\\.03734307692857991\ \(0\)\
\-\ tissues\\:\\ 0\\.036888446994044304\ \(0\)\
\-\ initially\\:\\ 0\\.036689843975393176\ \(0\)\
\-\ placement\\:\\ 0\\.036534352988295556\ \(0\)\
\-\ placed\\:\\ 0\\.036457699122671584\ \(0\)\
\-\ considered\\:\\ 0\\.036457699122671584\ \(0\)\
\-\ includes\\:\\ 0\\.036381755025251955\ \(0\)\
\-\ shoulder\\:\\ 0\\.036344045055732736\ \(0\)\
\-\ extremities\\:\\ 0\\.03555548234877378\ \(0\)\
\-\ traumatic\\:\\ 0\\.035453594033274693\ \(0\)\
\-\ process\\:\\ 0\\.03509047258710578\ \(0\)\
\-\ malignancy\\:\\ 0\\.035026143599126126\ \(0\)\
\-\ femoral\\:\\ 0\\.034773757411216376\ \(0\)\
\-\ diagnosed\\:\\ 0\\.03389098104443399\ \(0\)\
\-\ pain\\:\\ 0\\.033483966251153664\ \(0\)\
\-\ later\\:\\ 0\\.033482841924009674\ \(0\)\
\-\ risk\\:\\ 0\\.033429926231290194\ \(0\)\
\-\ required\\:\\ 0\\.03340359585900729\ \(0\)\
\-\ kidney\\:\\ 0\\.032869329561045525\ \(0\)\
\-\ signs\\:\\ 0\\.03269870430694609\ \(0\)\
\-\ was\\:\\ 0\\.03261121746702796\ \(0\)\
\-\ this\\:\\ 0\\.032153467051224606\ \(0\)\
\-\ less\\:\\ 0\\.03182972424942532\ \(0\)\
\-\ available\\:\\ 0\\.03174338762146123\ \(0\)\
\-\ inflammatory\\:\\ 0\\.03163672937042663\ \(0\)\
\-\ followed\\:\\ 0\\.031594451421546176\ \(0\)\
\-\ three\\:\\ 0\\.031406852048117995\ \(0\)\
\-\ while\\:\\ 0\\.03023727527307407\ \(0\)\
\-\ show\\:\\ 0\\.029701238357335777\ \(0\)\
\-\ clinical\\:\\ 0\\.02965117571611653\ \(0\)\
\-\ during\\:\\ 0\\.029634555844326036\ \(0\)\
\-\ days\\:\\ 0\\.02961796958200598\ \(0\)\
\-\ tenderness\\:\\ 0\\.029341017020268065\ \(0\)\
\-\ proximal\\:\\ 0\\.02922964124978149\ \(0\)\
\-\ treated\\:\\ 0\\.029135365454086935\ \(0\)\
\-\ year\\:\\ 0\\.028837445220182376\ \(0\)\
\-\ years\\:\\ 0\\.028679586873947303\ \(0\)\
\-\ for\\:\\ 0\\.028361345604346614\ \(0\)\
\-\ when\\:\\ 0\\.028261840375259275\ \(0\)\
\-\ following\\:\\ 0\\.028067539148575717\ \(0\)\
\-\ she\\:\\ 0\\.027850974648672366\ \(0\)\
\-\ include\\:\\ 0\\.027837627365137473\ \(0\)\
\-\ months\\:\\ 0\\.02723361219138038\ \(0\)\
\-\ distal\\:\\ 0\\.027184202982187468\ \(0\)\
\-\ if\\:\\ 0\\.027184202982187468\ \(0\)\
\-\ due\\:\\ 0\\.026893839777857084\ \(0\)\
\-\ common\\:\\ 0\\.02653338627967518\ \(0\)\
\-\ mild\\:\\ 0\\.026522018427651436\ \(0\)\
\-\ than\\:\\ 0\\.026522018427651436\ \(0\)\
\-\ prior\\:\\ 0\\.02617720965755725\ \(0\)\
\-\ symptoms\\:\\ 0\\.025599001425166266\ \(0\)\
\-\ can\\:\\ 0\\.024552148694216017\ \(0\)\
\-\ tumor\\:\\ 0\\.0244721294846665\ \(0\)\
\-\ woman\\:\\ 0\\.024366637304716554\ \(0\)\
\-\ had\\:\\ 0\\.023310826386944546\ \(0\)\
\-\ treatment\\:\\ 0\\.02228696123897743\ \(0\)\
\-\ seen\\:\\ 0\\.02202677329451454\ \(0\)\
\-\ within\\:\\ 0\\.02154848561252233\ \(0\)\
\-\ has\\:\\ 0\\.02137077584872202\ \(0\)\
\-\ that\\:\\ 0\\.02030364903610468\ \(0\)\
\-\ by\\:\\ 0\\.019868322655600453\ \(0\)\
\-\ from\\:\\ 0\\.018581671551712496\ \(0\)\
\-\ not\\:\\ 0\\.018470254215620863\ \(0\)\
\-\ an\\:\\ 0\\.017891055714116432\ \(0\)\
\-\ history\\:\\ 0\\.017875206619480034\ \(0\)\
\-\ ct\\:\\ 0\\.017812114739742983\ \(0\)\
\-\ at\\:\\ 0\\.017671907839726504\ \(0\)\
\-\ patient\\:\\ 0\\.015217346634534718\ \(0\)\
\-\ on\\:\\ 0\\.014130369645891903\ \(0\)\
\-\ is\\:\\ 0\\.012812840398927161\ \(0\)\
